Replies to post #185542 on Biotech Values

[poorgradstudent]

FGEN:

Wouldn't the competition be a negative for FGEN. Or are you suggesting that investors think that BMY might want to gobble FGEN up?

I think the response from the market in these cases is usually to consider it "validation" and look for other players. Perhaps that explains a bit of the bump, but it would seem a little overdone just for that.